FFO
RLMD icon

Fortitude Family Office’s Relmada Therapeutics RLMD Stock Holding History

Fortitude Family Office’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-252
Closed -$816 – 1368
2024
Q3 		$816 Hold
252
– – ﹤0.01% 1119
2024
Q2 		$756 Sell
252
-88
-26% -$318 ﹤0.01% 902
2024
Q1 		$1.58K Hold
340
– – ﹤0.01% 858
2023
Q4 		$1.41K Buy
+340
New +$1.01K ﹤0.01% 910

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fortitude Family Office's RLMD Position: Q4 2024 in Review

Fortitude Family Office sold out of Relmada Therapeutics (RLMD) in Q4 2024, closing a stake of 252 shares — an estimated $816 sold.

Fortitude Family Office first reported a position in RLMD in Q4 2023 and held it in 4 quarters. The position peaked at $1.58K in Q1 2024. 48 funds tracked by Wall St. Rank hold RLMD as of Q4 2024.

  • Fortitude Family Office reported no remaining Relmada Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Fortitude Family Office sold 252 Relmada Therapeutics shares in Q4 2024, an estimated $816.
  • Fortitude Family Office first reported a position in Relmada Therapeutics in Q4 2023 and held it in 4 quarters.
  • Fortitude Family Office's Relmada Therapeutics position peaked at $1.58K in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2024.

Based on Fortitude Family Office's 13F filing for Q4 2024, filed 10 Jan 2025.